Skip to Content
Merck

719927

Resomer® RG 756 S, Poly(D,L-lactide-co-glycolide)

ester terminated, lactide:glycolide 75:25, Mw 76,000-115,000

Synonym(s):

PLGA

Sign In to View Organizational & Contract Pricing.

Select a Size


About This Item

Linear Formula:
[C3H4O2]x[C2H2O2]y
CAS Number:
MDL number:
UNSPSC Code:
12162002
NACRES:
NA.23
Technical Service
Need help? Our team of experienced scientists is here for you.
Let Us Assist
Technical Service
Need help? Our team of experienced scientists is here for you.
Let Us Assist

Product Name

Resomer® RG 756 S, Poly(D,L-lactide-co-glycolide), ester terminated, lactide:glycolide 75:25, Mw 76,000-115,000

SMILES string

O2C(C(=O)OC(C2=O)C)C.O1CC(=O)OCC1=O

InChI

1S/C6H8O4.C4H4O4/c1-3-5(7)10-4(2)6(8)9-3;5-3-1-7-4(6)2-8-3/h3-4H,1-2H3;1-2H2

InChI key

LCSKNASZPVZHEG-UHFFFAOYSA-N

form

amorphous

feed ratio

lactide:glycolide 75:25

mol wt

Mw 76,000-115,000

degradation timeframe

<6 months

viscosity

0.71-1.0 dL/g, 0.1 % (w/v) in chloroform(25 °C, Ubbelohde) (size 0c glass capillary viscometer)

transition temp

Tg 49-55 °C

storage temp.

2-8°C

Quality Level

Application

Controlled release
Poly (lactic-co-glycolic acid) 75:25 copolymer may be used to design a controlled drug delivery implant.

Legal Information

Product of Evonik
RESOMER is a registered trademark of Evonik Rohm GmbH

Storage Class

11 - Combustible Solids

wgk

WGK 3

flash_point_f

Not applicable

flash_point_c

Not applicable


Choose from one of the most recent versions:

Certificates of Analysis (COA)

Lot/Batch Number

Don't see the Right Version?

If you require a particular version, you can look up a specific certificate by the Lot or Batch number.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

An in-situ forming implant formulation of naltrexone with minimum initial burst release using mixture of PLGA copolymers and ethyl heptanoate as an additive: In-vitro, ex-vivo, and in-vivo release evaluation.
Kamali H, et al.
Journal of drug delivery science and technology, 47, 95-105 (2018)
Rongcai Liang et al.
International journal of pharmaceutics, 454(1), 344-353 (2013-07-23)
Peptide or protein degradation often occurs when water flows into the dosage form. The aim of this study was to investigate the effect of water on exenatide acylation in poly(lactide-co-glycolide) (PLGA) microspheres. Exenatide-loaded PLGA microspheres were incubated at different relative
Jingwei Tian et al.
Food and chemical toxicology : an international journal published for the British Industrial Biological Research Association, 52, 143-152 (2012-11-21)
Continuous dopaminergic stimulation (CDS) is an important drug development strategy in the treatment of Parkinson's disease (PD). Rotigotine is a non-ergoline D(3)/D(2)/D(1) dopamine receptor agonist for treating PD. As a new treatment option for CDS, rotigotine-loaded microspheres (RoMS), long-acting sustained-release
Teresa Musumeci et al.
International journal of pharmaceutics, 440(2), 135-140 (2012-10-20)
Melatonin, a neurohormone secreted by the pineal gland, is able to modulate intraocular pressure (IOP). The aim of this study was to generate nanoparticle (NPs) sustained release formulations that allow to extend the pre-corneal residence time of melatonin, thus prolonging
Maria Kirzhner et al.
Ophthalmology, 120(6), 1300-1304 (2013-02-13)
To compare wrapped and polymer-coated hydroxyapatite implants in children undergoing primary enucleation with no adjuvant therapies. Retrospective, interventional cohort study. All children undergoing primary enucleation without adjuvant therapies between 1999 and 2009 at a tertiary pediatric cancer hospital. Review and

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service